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Background: Atopic dermatitis (AD) is the most common chronic inflammatory skin dis-
ease in infancy with a complex pathology. In adults, the clinical severity of AD has been 
associated with increases in T helper cell type (Th) 2, Th22, and Th17 serum markers, 
including high levels of CC chemokine ligand (CCL) 17 and CCL22 chemokines.
Objective: To explore the possible association between serum chemokine levels and 
AD severity in infants with moderate-to-severe AD and elevated immunoglobulin E (IgE).
subjects and methods: Serum samples (n = 41) obtained from a randomized, dou-
ble-blind, and clinical dietary intervention study were used to study biomarkers in infants 
with AD. Baseline- and post-intervention samples (4 months) were used, six chemokines 
and nine ratios thereof were analyzed using Luminex and correlated to AD severity. In 
the initial study, the infants were randomized to receive extensively hydrolyzed whey-
based formula without (control) or with short-chain galacto-oligosaccharides/long-chain 
fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).
results: 31 Infants up to 11  months of age, with an objective-SCORAD score 
(oSCORAD) ≥  20 and elevated total-IgE and/or specific-IgE levels were included. In 
time, the median oSCORAD decreased in both groups by −8 (control, p < 0.05; active, 
p  <  0.01). Irrespective of dietary intervention, several changes in Th2 chemokines 
Abbreviations: Active group, group of infants receiving the whey based extensively hydrolysed infant formula with short-chain 
galacto-oligosaccharides, long-chain fructo-oligosaccharides and Bifidobacterium breve M-16V; AD, atopic dermatitis; AMC, 
Academic Medical Centre, Amsterdam, the Netherlands; CCL, CC chemokine ligand (-17, -20, -22); Control group, group of 
infants receiving the whey based extensively hydrolysed infant formula; CXCL, CXC chemokine ligand (-9, -10, -11); DC, den-
dritic cell; HOME, Harmonising Outcome Measures for Eczema; IgE, immunoglobulin E (total, specific); IL, interleukin (-4, 
-5, -13, -22, -31); IFN, interferon (−γ); lcFOS, long-chain fructo-oligosaccharides; IQR, interquartile range (Q1–Q3); MWU, 
Mann–Whitney U-test; oSCORAD, objective SCORing Atopic Dermatitis score; scGOS, short-chain galacto-oligosaccharides; 
SCORAD Score, scoring atopic dermatitis score, clinical tool for scoring AD severity; Th, T helper cell type (1, 2, 17, 22); W-test, 
Wilcoxon matched-pairs signed rank test.
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(CCL17 and CCL22), inflammatory chemokine (CCL20), and the Th1 chemokine, CXC 
chemokine ligand (CXCL) 9, were detected over time. Overall CCL17 correlated to 
oSCORAD (r = 0.446, p < 0.01). After 4 months of dietary intervention, CXCL9 was 
higher (p < 0.01) in the active group compared with control [active, 2.33 (1.99–2.89); 
controls, 1.95 (1.77–2.43) log 10 median (range)]. In addition, a reduction in Th2/Th1 
chemokine ratios for CCL17/CXCL9, CCL22/CXCL9, CCL20/CXCL10, and CCL20/
CXCL11 was detected associated with the active intervention.
conclusion: While this study is small and exploratory in nature, these data contribute to 
immune biomarker profiling and understanding of AD in infants.
Keywords: atopic dermatitis, atopic dermatitis severity, chemokine profiles, dietary intervention, infants, T helper 
cell type 2/T helper cell type 1 response
inTrODUcTiOn
atopic Dermatitis (aD) in infancy
The natural course of atopic manifestations, also described as the 
atopic march, refers to AD and food sensitization during infancy 
and the development of allergic rhinitis or allergic asthma later in 
life (1, 2). AD, also known as allergic eczema, is the most common 
chronic inflammatory skin disease in infancy and childhood. The 
pathophysiology of AD is complex and involves a compromised 
skin barrier function, which allows penetration of environmental 
factors (including irritants, allergens, and bacteria) leading to 
inflammation and allergic sensitization (3, 4).
Upon cellular damage, keratinocytes react by releasing pro-
inflammatory mediators and chemokines to attract leukocytes 
which follow a chemokine gradient to the site of inflammation 
(5, 6). Chemokine production at site of inflammation leads to 
leukocyte migration. Several chemokines [classically character-
ized within a T helper cell type (Th) 1-type of response: CXC 
chemokine ligand (CXCL) 9, CXCL10, and CXCL11; Th2 type 
of response: CC chemokine ligand (CCL) 17 and CCL22; and 
for inflammation: CCL20] have been suggested to be involved 
in development of AD (7). In adults, the clinical severity of AD 
has been associated with increases in Th2, Th22, and Th17-type 
of immune markers.
Only limited studies regarding the pathology of early pediatric 
AD are available and therefore only associations of disease activ-
ity to a few serum biomarkers [i.e., CCL17, CCL22, CCL27, and 
immunoglobulin E (IgE)] are known in infants (8–10). Serum 
levels of CCL17 detected in children with AD are higher than 
in healthy controls (11). In addition, significant correlations 
have been found between CCL17 and CCL22 and AD severity in 
infants as well as in adults (12, 13). Recently, immune activation in 
non-lesional skin in pediatric patients with AD has been detected 
(8). Alterations in skin-derived immunity and consequently the 
skin barrier function may occur during the early-onset phase of 
AD. For instance, Th2 (IL13, IL31, and CCL17), Th22 (IL22 and 
S100As), and some Th1-skewing mediators [interferon (IFN) 
γ and CXCL10] have been detected in the skin (8). A Th2 type 
of immunity classically leads to production of interleukins IL4, 
IL5, and IL13, which may locally induce IgE and eosinophilic 
activation, which collectively leads to allergic as well as atopic 
disease manifestations (14). Therefore, it is of interest to study 
the development of Th2/Th1 chemokine ratios in association to 
the severity of AD and the impact of specific dietary intervention.
Dietary intervention and aD
Evidence suggests that the microbiome of both the lung and gut are 
involved in the pathogenesis of asthma and allergy (15). Notably, 
recent studies have demonstrated essential differences between 
the microbiome profiles of the lungs from healthy and asthmatic 
subjects (16). It has been suggested that microbial modulations 
may induce beneficial effects in AD management, by decreasing 
the Th2-type response and increasing the Th1-type response 
(17, 18). In a dietary intervention study, a specific synbiotic mix-
ture of prebiotic short-chain galacto-oligosaccharides (scGOS), 
long-chain fructo-oligosaccharides (lcFOS), and a probiotic strain 
Bifidobacterium breve M-16V resulted in significant improve-
ment in IgE-associated AD severity in infants (19), leading to the 
prevention of asthma-like symptoms and asthma medication use 
at the 1-year follow-up (20).
Various pro-inflammatory mediators are released by mast cells 
upon activation and trigger allergic responses such as asthma, 
allergic rhinitis, and AD. In addition, anti-inflammatory and 
direct, microbiota independent, immune-modulatory properties 
of scGOS/lcFOS mixtures on human monocyte derived dendritic 
cells (DCs) have been suggested to induce regulatory T  cells, 
which represents a way to induce maintenance of intestinal 
homeostasis (21).
Galectins are defined as lectins having both galactose-binding 
ability and specific regulatory amino-acid sequences. More 
specifically, galectin-9 is known to bind IgE, suppress IgE–anti-
gen complex formation and, hence prevents pro-inflammatory 
mediator release from mast cells (22). In addition, galectin-9 
expression by intestinal epithelial cells and serum galectin-9 
levels has been shown to correlate with reduced acute allergic skin 
reaction and mast cell degranulation (23). A recent published 
in  vivo study showed that the dietary intervention with prebi-
otics and B. breve M16-V enhances galectin-9 and suppresses 
allergic symptoms of OVA-allergic mice. This is associated with 
a reduced Th2 activation and increased Tregs frequency in these 
mice (24). This leads to the conclusion that dietary intervention 
may be associated with decreased maturation and activation of 
DCs, changing immune responsiveness (25). Therefore, in this 
study, we explored the immunological mechanisms behind the 
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development of AD in infants with moderate-to-severe AD and 
elevated IgE levels.
sUBJecTs anD MeThODs
subjects
Infants, aged 0–11 months, were recruited (from 2012 to 2014) at 
the pediatric and dermatology outpatient clinic in a tertiary refer-
ral center, Academic Medical Centre of Amsterdam. The objective 
SCORing Atopic Dermatitis score (oSCORAD) of ≥20 points, 
corresponding with moderate-to-severe AD, was required for 
enrollment in the study. In addition, elevated total and/or specific 
IgE levels were also required for inclusion. The cut-off value for 
elevated total IgE was considered as >5 kU/L at age <3 months and 
>15 kU/L at age >3 months. Specific IgE against aero-allergens or 
food allergens were considered elevated if >0.35 kU/L (19).
The use of topical corticosteroids was allowed under the guid-
ance of the infants’ own general practitioner or dermatologist. 
However, it was recommended to adhere to a very strict policy 
with regards to the prescription of topical steroids. Topical steroid 
use was also permitted during the intervention period when 
the topical steroids where already prescribed before start, as it 
is unethical to withhold infants of AD treatment. Infants with 
severe cow’s milk allergy (history of anaphylactic reaction) were 
excluded. Infants treated with systemic corticosteroids, antibiot-
ics or anti-mycotics 4 weeks, or antihistamines 48 h before enroll-
ment were excluded. Infants with severe medical problems other 
than allergies were also ineligible for study inclusion. Infants with 
an expected daily intake of minimal 500 mL infant formula per 
day were eligible. Following enrollment, partial breastfeeding was 
allowed, and infants were required to drink ≥500 mL/day of the 
study infant formula.
study Design
A randomized double–blind clinical intervention study was 
conducted. All infants were randomized to receive a newly devel-
oped extensively hydrolyzed whey-based infant formula (eHF; 
Nutricia, Cuijk, the Netherlands) without (control group) or with 
prebiotic scGOS, long-chain fructo-oligosaccharides (lcFOS) and 
the probiotic strain B. breve M-16V (active group) for 4 months. 
This specific mixture consisted of 90% scGOS, 10% lcFOS 
(0.8 g/100 mL), and B. breve M-16V at a dose of 1.0 × 108 cfu/g 
(Morinaga Milk Industry Co., Ltd., Tokyo, Japan).
Hospital visits were scheduled at screening, baseline (week 0) 
and after dietary intervention (4 months later). Gestational age, 
medical history, intake of infant formula, the SCORAD score 
(26), and blood samples were obtained at screening to investigate 
eligibility for randomization.
Biological samples were obtained before randomization (base-
line) and at the end of intervention (4 months later), and oSCO-
RAD score was assessed. During the study, parents maintained a 
diary to record daily intake of study product, fecal consistency, 
and inter-current illness.
scOraD score
The most used and validated severity scale for AD is the 
SCORAD score, developed by the European Task Force on 
Atopic Dermatitis (ETFAD) (26) and is still one of the used 
measurements in AD trials by The Harmonising Outcome 
Measures for Eczema initiative (27). However, subjective symp-
toms, such as pruritus and sleep disturbance, are estimated by 
parents, which can be highly subjective. Therefore, the ETFAD 
modified SCORAD score (A/5 +  7/2) calculated by excluding 
the subjective symptoms (oSCORAD) was used in this study 
(28, 29). AD severity was classified as follows: oSCORAD 0–14 
points mild AD, 15–40 points moderate AD, and >40 points 
severe AD (29).
Blood samples
Serum samples were obtained at screening and following 
4  months of dietary intervention. Sample aliquots were stored 
at −80°C until analysis. Specific-IgE levels (total IgE, specific 
IgE against aero-allergens and food allergens) were tested with 
standardized methods using the CAP System FEIA (Phadia 
Diagnostics, Uppsala, Sweden). Using an in-house developed 
and validated (ISO9001 certified) multiplex immunoassay 
(Laboratory of Translational Immunology, University Medical 
Centre Utrecht) based on Luminex technology (xMAP, Luminex, 
Austin, TX, USA), the 90-plex assay was performed as described 
previously (30–32). Knowing the role of chemokines within AD 
pathology, specifically six chemokines (CCL17, CCL20, CCL22, 
CXCL9, CXCL10, and CXCL11) and nine chemokine Th2/Th1 
ratios (CCL17–CCL20–CCL22 and CXCL9–CXCL10–CXCL11) 
were correlated to AD severity. After preabsorption with hetero-
block (Omega Biologicals, Bozeman, MT, USA), acquisition 
was performed using Biorad FlexMAP3D (Biorad Laboratories, 
Hercules, CA, USA) in combination with xPONENT software 
version 4.2 (Luminex). Data were analyzed by five-parametric 
curve fitting using Bio-Plex Manager software, version 6.1.1 
(Biorad).
initial Primary study Outcome
The initial primary study outcome was change in severity of AD 
(oSCORAD) after 4 months of dietary intervention. However, the 
dietary intervention study was ended prematurely due to limited 
recruitment of this specific study population (AD in infants with 
elevated IgE levels). The specific requirements for study inclusion, 
however, did allow us to explore associations of AD severity and 
chemokine profiles in this unique population of infants with AD 
and elevated IgE levels.
statistical analysis
Statistical analyses were performed using SPSS version 24 (IBM 
SPSS Statistics for Windows, Armonk, NY, USA) and GraphPad 
prism® version 7.0 (GraphPad Software, La Jolla, CA, USA), and/
or SAS® Enterprise Guide 4.3 or higher (SAS Institute Inc., Cary, 
NC, USA). Statistical analyses of the exploratory measurements 
were conducted using non-parametric testing, with Wilcoxon 
matched-pairs signed rank test (W-test) for comparison within 
groups and with the Mann–Whitney U test (MWU) for non-
paired, non-parametric comparison between groups. In addition, 
a two-tailed non-parametric Spearman correlation analysis was 
used to determine the overall associations between biomark-
ers as well as with clinical severity of AD (oSCORAD). Due to 
FigUre 1 | Flowchart of study inclusion and exclusion.
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exploratory nature, differences were considered significant with 
a p-value of <0.05.
resUlTs
infant characteristics
Overall, 53 infants with moderate-to-severe AD were screened. 
Of these, 31 infants had elevated IgE levels and were therefore 
considered eligible for randomization. In total, 26 infants com-
pleted the study (Figure 1). Baseline characteristics (n = 31) are 
shown in Table 1.
The infants were well balanced over the study groups with 
respect to the baseline characteristics; only significant differ-
ences for length and weight were observed; infants in the control 
group were smaller in respect to length, weight. At baseline, the 
length-for-age z-scores for infants in the control group were 
significantly lower (p < 0.05) than the active group [mean (SD) 
−0.4667 (0.9155) versus 0.3125 (0.9465), respectively]. The 
weight-for-age z-scores were also significantly lower (p < 0.05) 
in the control group than the active group with a mean (SD) of 
−0.5333 (0.7432) and 0.125 (0.8062), respectively.
Atopic dermatitis severity was classified as moderate-to-
severe with a median oSCORAD of 23 (Q1–Q3 =  21–27). All 
infants were born at term with a median gestational age of 
39 weeks, and only 12.9% of the infants were born via cesarean 
section. The mean age of infants at the time of inclusion was 
7 months (median 6, range 2–11 months). The male/female ratio 
was approximately 2:1 in both study groups. The majority (80%) 
of infants were of Caucasian descent. At baseline, total IgE was 
comparable in both groups. In addition, 83.9% of the infants 
were sensitized to at least one food allergen; 29% to at least one 
aero-allergen, which was comparable in both groups. For all 
infants, topical corticosteroids were prescribed before screening 
for this study. The topical corticosteroids were used in 93.5% 
of the infants for a mean (SD) of 124.6 (73.1) days before start 
of dietary intervention. Topical corticosteroid use was evenly 
distributed between the study groups, with a median (Q1–Q3) 
of 135 (67–150) days of topical steroid use in the control group 
and 113 (65–182) days in the active group, with no significant 
differences observed.
Low potency topical corticosteroids (hydrocortisone acetate 
1%) were most commonly used (83.9%) compared with moderate 
potency triamcinolone acetonide 0.1% (29%) and high potency 
mometasone furoate 0.1% (9.7%).
The median [interquartile range (Q1–Q3)] for exclusive 
breastfeeding before study enrollment was 0 (0–3) months in 
the control group and 3 (0–6) months in the active group, but 
this was not significantly different. Cows’ milk protein was 
introduced at a median (Q1–Q3) of 0 (0–3) months and 3 (0–6) 
months in the control and active groups, respectively, (p > 0.05). 
Complementary feeding was first introduced at a median (Q1–Q3) 
of 5 (4–6) months among all infants.
effect on severity of aD
At baseline, oSCORAD between the study groups was compara-
ble, with a median (Q1–Q3) oSCORAD in the control group of 
24 (21–27) and 21 (20–26) in the active group. After 4 months of 
dietary intervention, the average oSCORAD decreased in those 
infants (n = 26) who completed the study. The median change 
in both groups of −8, resulted in a median (Q1–Q3) post-
intervention oSCORAD of 17 (12–21) in the control group and 
13 (12–17) in the active group.
TaBle 1 | Baseline characteristics of the clinical study (n = 31).
characteristic control group (n = 15) active group (n = 16) p Values
Male, n (%) 9 (60.0) 11 (68.8) 0.72
Age (months)
Mean (±SD) 6.5 (1.8) 7.4 (2.4)
Median (Q1–Q3) 6 (6–7) 8 (6–10) 0.15
Range 4–10 2–11
Ethnicity, n (%) 0.82
Caucasian/White 11 (73.3) 13 (81.25)
African/Black 1 (6.7) 0
Asian 1 (6.7) 0
Combination of above or other 2 (13.3) 3 (13.3)
Gestational age (mean ± SD, weeks) 39.8 (1.2) 39.4 (1.8) 0.71
Birth weight (mean ± SD, g) 3,538.0 (428.6) 3,820.3 (718.2) 0.14
Delivery by cesarean section, n (%) 1 (6.7) 3 (18.8) 0.60
Length-for-age (mean ± SD, z-scores) −0.4667 (0.9155) 0.3125 (0.9465) 0.02
Weight-for-age (mean ± SD, z-scores) −0.5333 (0.7432) 0.125 (0.8062) 0.03
Head circumference-for-age (mean ± SD, z-scores) −0.2143 (1.369) 0.0625 (0.7719) 0.32
Started with breastfeeding, n 13 14
Duration of exclusive breast feeding (mean ± SD, months) 1.5 (2.1) 3.0 (3.1) 0.14
Time of first introduction cow’s milk protein (mean ± SD, months) 1.5 (2.1) 3.9 (4.3) 0.10
Time of first solid food introduction (mean ± SD, months) 5.3 (1.1) 5.2 (1.2) 0.86
oSCORAD score (mean ± SD) 26.53 (4.307) 24.94 (5.221) 0.22
Any topical corticosteroid used
Yes, n (%) 14 (93.3) 15 (93.8) 1.00
Hydrocortisone acetate 1%, n 12 14 0.65
Triamcinolone acetonide 0.1%, n 5 4 0.70
Mometasone furoate 0.1%, n 1 2 1.00
Total immunoglobulin E (IgE)
log 10 Mean (SD) 1.761 (0.4890) 1.562 (0.3508) 0.11
Total IgE log 10 min–max 1.000–2.963 0.8451–2.332
Sensitization to aero-allergens 0.24
Negative, n (%) 7 (46.7) 11 (68.8)
Positive, n (%) 6 (40.0) 3 (18.8)
Missing, n (%) 2 (13.3) 2 (12.5)
Sensitization to food allergens 0.65
Negative, n (%) 3 (20.0) 2 (12.5)
Positive, n (%) 12 (80.0) 14 (87.5)
Parental allergies: at least 1 positive allergic manifestations
Mother (total 31), n (%) 6 (40) 6 (37.5) 1.00
Father (total 26), n (%) 7 (58.3) 7 (50) 0.71
Siblings in household (blood related)
None 10 (66.7) 9 (56.3) 0.72
1 2 (13.3) 5 (31.3) 0.39
2 or more 3 (20) 2 (12.6) 0.65
Day care attendance [yes, n (%)] 11 (73.3) 12 (75.0) 1.00
Exposure to smoking in household [yes, n (%)] 5 (33.3) 4 (25.0) 0.70
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Interestingly, only four out of thirteen (31%) infants in the 
active group retained an oSCORAD above 15 (moderate AD) 
compared with eight out of thirteen (62%) infants in the control 
group. AD exacerbations occurred in 8 out of 26 infants (4 in 
both groups 30.8%) during dietary intervention period. The use 
of topical steroids during the dietary intervention period appears 
similar in both groups (p > 0.05) with a median (Q1–Q3) topical 
steroid use of 118.5 (113.5–120.8) days in the control group and 
117.0 (113.0–121.5) days in the active group.
exploratory immune Profiles in aD
In total, 41 serum samples obtained from the clinical study were 
used for exploring the biomarker profiles of infants with moderate 
to severe AD and elevated IgE levels. For these infants from which 
serum samples were obtained, reduction of oSCORAD at baseline 
and after 4 months of dietary intervention is shown in (Figure 2). 
Non-parametric analyses were performed and indicated within 
the figures. Small sample sizes are in general a good argument 
to use non-parametric statistics, as possible skewness in the 
data may not be revealed. Additional parametric analysis using 
ordinary one-way ANOVA was performed, to show robustness of 
the data. The analysis indicated no differences between the groups 
at baseline and confirmed the significant decline within control 
(p < 0.001) as well as within active (p < 0.0001) of oSCORAD, 
which support the non-parametric analysis.
Several chemokines were measured in serum at baseline and 
at the end of intervention and correlated to AD severity. We 
detected an overall significant correlation between oSCORAD 
FigUre 2 | Reduction of atopic dermatitis severity over time. Individual 
oSCORAD of the control (open dots) and active (closed triangles) groups at 
baseline and after 4 months of dietary intervention, for infants from which 
serum samples were available (n = 41). Line represents median ± interquartile 
range. Significant differences within the groups are depicted with asterisks 
(non-paired W-test, *p < 0.05, **p < 0.01).
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and CCL17 levels (Spearman r =  0.446, p <  0.01) and CCL22 
(Spearman r = 0.288, p < 0.05) (Table 2). In addition, at baseline 
(n =  18), a significant correlation was detected between levels 
of IgE and chemokines CCL17 (Spearman r = 0.721, p < 0.01) 
and CCL22 (Spearman r =  0.549, p <  0.05). Moreover, a sig-
nificant correlation between galectin-9 and chemokines CCL20 
(Spearman r = 0.585, p < 0.05) and CCL22 (Spearman r = 0.492, 
p < 0.05) was observed.
Total IgE and galectin-9 were measured in serum at baseline 
and at the end of intervention. Both levels, however, did not 
significantly change in either group (Figures 3A,B). The levels 
of Th2 driving chemokines CCL17 and CCL22 significantly 
changed over time (Figures 3C,D). In the control group, a signifi-
cant reduction of CCL22, but not CCL17, was detected (W-test, 
p < 0.05), whereas in the active group, both CCL17 and CCL22 
were significantly reduced (W-test, p < 0.05, for both). CCL20, a 
strong chemokine for DCs, remained unchanged in the control 
group, yet was significantly reduced in the active group after 
4 months of dietary intervention (W-test, p < 0.05) (Figure 3E). 
While no differences were observed in the release of Th1-driving 
chemokines CXCL9, CXCL10, and CXCL11 in the control group, 
after 4 months of dietary intervention, CXCL9 levels were signifi-
cantly higher in the active group as compared with the control 
group (MWU, p < 0.01). The dietary intervention resulted in a 
higher CXCL9 level (log 10 median, 2.33; range 1.99–2.89) in the 
active group as compared with the control group (1.95; 1.77–2.43) 
(Figures 3F–H). Moreover, additional parametric analysis using 
ordinary one-way ANOVA confirm our statistical findings within 
the serum biomarker analysis, although small sample size may not 
reveal possible skewness of the data and therefore the parametric 
analysis are not shown.
chemokine ratios change Over Time and 
due to Dietary intervention
Knowing that the immune balance between chemokines deter-
mines the type of cells recruited toward the lesional site, which 
in case of AD is the skin, nine chemokine ratios (Th2/Th1) 
were analyzed. After 4 months of dietary intervention, signifi-
cantly lower CCL17/CXCL9 (MWU, p < 0.05), CCL20/CXCL9 
(MWU, p < 0.05), and CCL22/CXCL9 (MWU, p < 0.01) ratios 
were observed in the active group as compared with the con-
trol group. Moreover, a reduction in CCL17/CXCL10 (W-test, 
p  =  0.0781), CCL20/CXCL9 (W-test, p  <  0.05), CCL20/
CXCL10 (W-test, p  <  0.05), and CCL20/CXCL11 (W-test, 
p <  0.01) ratios were observed over time within the active 
group. Interestingly, these ratios did not change in the control 
group over time (Figure 4).
DiscUssiOn
Based on the hygiene hypothesis, the immunological basis in 
children with low microbial stimuli in early life is associated 
with higher Th2-immune responses (33, 34). Several studies have 
linked the infant microbiota of the gastrointestinal tract, as well as 
the skin and respiratory tract to the risk of developing childhood 
allergic diseases (35). This suggests that the microbiome plays an 
important role in early immunologic development (36). Several 
factors responsible for the microbial dysbiosis associated with 
allergy development are cesarean delivery (37), lack of breast milk 
(38), and antibiotics use in early life (39). Specific dietary inter-
ventions have been shown to alter microbial development and 
the immune system by changing the Th2/Th1 balance (17, 18). 
An immunological imbalance may activate the secretion of IL4, 
IL5, and IL13 production, which may be involved in the induc-
tion of IgE and eosinophil activation, leading to development of 
allergic manifestations (14). In this exploratory setting, a study 
with specific dietary intervention in infants with moderate-to-
severe AD and elevated IgE levels was used to investigate changes 
in chemokine profiles. The changes in chemokine ratios within 
infants receiving dietary intervention suggest a specific change in 
immune response where the Th2/Th1 balance skews away from 
the allergic phenotype.
It has previously been reported that dietary intervention 
with scGOS/lcFOS plus B. breve M-16V in infants with AD and 
TaBle 2 | Two-tailed Spearman correlation of chemokines and T helper cell type 
(Th) 2/Th1 ratio to atopic dermatitis severity (oSCORAD) (n = 41).
chemokine spearman r p Value
CC chemokine ligand (CCL) 17 0.446 0.002 
CCL20 0.163 0.273
CCL22 0.288 0.049
CXC chemokine ligand (CXCL) 9 −0.177 0.234
CXCL10 0.034 0.824
CXCL11 0.042 0.780
CCL17/CXCL9 0.375 0.009
CCL17/CXCL10 0.318 0.029
CCL17/CXCL11 0.364 0.012
CCL20/CXCL9 0.239 0.105
CCL20/CXCL10 0.032 0.832
CCL20/CXCL11 0.032 0.832
CCL22/CXCL9 0.259 0.079
CCL22/CXCL10 0.187 0.207
CCL22/CXCL11 0.187 0.208
FigUre 3 | Allergy markers measured in serum of the control (open dots, n = 20) and active (closed triangles, n = 21) groups before and after dietary intervention. 
Immunoglobulin E (IgE) (a), galectin-9 (B), CC chemokine ligand (CCL) 17 (c), CCL22 (D), CCL20 (e), CXC chemokine ligand (CXCL) 9 (F), CXCL10 (g), and 
CXCL11 (h). Line represents median ± interquartile range. Significant differences within the groups are depicted with asterisks (non-paired W-test, *p < 0.05)  
and between groups (using Mann–Whitney U-test, **p < 0.01).
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elevated IgE levels resulted in a significant improvement in AD 
severity (19), eventually leading to the prevention of asthma-like 
symptoms later in life (20). In this study, infants presenting with 
AD and elevated IgE levels were included to investigate the AD 
pathology within this unique population. While we did not find 
a direct influence on total IgE levels, galectin-9 tended to increase 
FigUre 4 | Chemokine ratios calculated in the control (open dots, n = 20) and active (closed triangles, n = 21) groups before and after dietary intervention. CC 
chemokine ligand (CCL) 17/CXC chemokine ligand (CXCL) 9 (a), CCL17/CXCL10 (B), CCL22/CXCL9 (c), CCL20/CXCL9 (D), CCL20/CXCL10 (e), and CCL20/
CXCL11 (F). Line represents median ± interquartile range. Significant differences within the groups are depicted with asterisks (non-paired W-test, *p < 0.05, 
**p < 0.01) and between groups (using Mann–Whitney U-test, *p < 0.05, **p < 0.01).
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after dietary intervention, especially in the active group, although 
this did not reach statistical significance. The time frame and size 
of this study may have been too short and too small to observe 
any potential differences in IgE. However, changes in serum 
chemokine profiles including, CCL17, CCL20, CCL22, CXCL9, 
CXCL10, and CXCL11 were detected.
In early AD, immune reactivity is skewed toward a Th2-type 
response; during the acute phase keratinocytes, DCs and dermal 
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fibroblasts produce CCL17 and CCL22, thereby recruiting Th2 
cells via CCR4 (6, 40, 41). Moreover, IFNγ-induced Th1-associated 
CXCR3 ligands CXCL9, CXCL10, and CXCL11 can be measured 
in AD patients (42–44) and are known to play a role in the chronic 
phase of AD (45, 46). Furthermore, while excess Th2 activation 
characterizes AD in both children and adults, Th17 polarization 
is also highly activated at disease initiation in pediatric AD. 
The inflammatory chemokine CCL20 was previously observed 
to be significantly higher in the lesions of the skin of children 
younger than 5 years of age as compared with adults (8, 12). In 
this study, decreased levels of Th2-driving chemokines CCL17 
and CCL22 and inflammatory chemokine CCL20 were detected, 
while the level of Th1-driving chemokine CXCL9–11 changed 
after 4 months of dietary intervention. These results suggest that 
dietary intervention with prebiotics scGOS/lcFOS and a probi-
otic B. breve skews the allergic phenotype from a Th2-dominant 
toward a Th1-type immune response. In early life, immune skew-
ing toward Th1 responsiveness is essential and is actively present 
(8). It has been reported that high Th2-associated CCL22 and low 
Th1-associated CXCL10 levels in cord blood (including CCL22/
CXCL10) precedes IgE-mediated allergic sensitization in early life 
(47). Moreover, high cord blood levels of CCL17 and CCL22 were 
shown to precede allergy development during the first 6  years 
of life (48). Within our study, we detected significant positive 
association between IgE and CCL17, IgE and CCL22, galectin-9 
and CCL20, and galectin-9 and CCL22 at baseline. Of these, 
CCL17 is a commonly used biomarker for AD severity, primarily 
in adults (13, 49). We also observed that CCL17 was significantly 
associated with disease severity (oSCORAD) in infants. Although 
age in itself may affect the development of AD, within our study, 
specifically the Th2/Th1 chemokine ratios were reduced after 
4 months of dietary intervention in the active group, as can be 
seen in (Figure 4). This is also suggestive for the hypothesis that 
the changes (decrease) in chemokine level precede changes in IgE 
level in association of changes in AD severity. Although correla-
tion analysis does not establish a cause-and-effect relationship, 
we show associations of serum biomarkers, ratios and changes 
herein to changes observed in AD severity (oSCORAD).
This study has several limitations. The specific requirements 
for study inclusion limited recruitment and therefore only a 
small sample size was enrolled. However, the uniqueness of the 
included group did allow us to explore associations between 
AD severity and chemokine profiles in this population of young 
infants with AD and elevated IgE levels. Heterogeneity between 
studies with dietary interventions are high, and therefore focused 
clinical randomized controlled trials are needed to understand 
the potential role and underlying mechanism of these dietary 
interventions in children with AD (50). As it is unethical to with-
hold infants with AD this treatment, the use of topical steroids 
was permitted during the intervention period when the topical 
steroids where already prescribed before start of intervention. 
However, topical corticosteroids were equally distributed in both 
groups at baseline (Table  1) and their use during the dietary 
intervention period appears similar in both groups, with a median 
of 118.5 days (control), and 117 days (active) with no significant 
differences. Local corticosteroid use was therefore not included 
as a confounding variable. In total, six infants received oral 
antibiotics for adverse events including fever and/or respiratory 
tract infections during the dietary intervention. As the antibiotic 
use was equally distributed in both groups (three infants from 
each group), these infants were not excluded from the serum 
analyses. Due to challenges with obtaining blood samples from 
infants, at both time points there were missing blood samples 
or not enough blood for serum analyses due to priority of total 
and/or specific IgE analyses because it was an inclusion criteria 
to have elevated total or specific IgE levels. Therefore, only 41 
serum samples obtained from the clinical study were used in this 
current study to explore biomarker profiles in these AD infants. 
Despite this limited number of samples, significant changes and 
associations were observed in Th2- and Th1-chemokine profiles. 
In addition, due to the exploratory nature of this study, correction 
for multiple testing was not conducted. Small sample sizes are 
in general a good argument to use non-parametric statistics, as 
possible skewness in the data may not be revealed. The additional 
parametric analysis showed robustness of the data, although 
confirmation of our results in larger cohorts is needed.
In conclusion, this study provides interesting insights into 
the complex pathology of AD and suggests that chemokine pro-
files and ratios may be useful for detecting a change in allergic 
manifestation. Furthermore, dietary intervention in infants with 
AD was associated with an improvement in Th2/Th1 balances, 
skewing away from the allergic phenotype.
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